NCT01155089已完成不适用
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Anastrozole 1 mg Tablets Under Fed Conditions
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- bioequivalence determined by statistical comparison Cmax
研究概览
简要总结
The objective of this study was to prove the bioequivalence of Anastrozole Tablet under fed conditions
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening
排除标准
- •Positive test for HIV, Hepatitis B, or Hepatitis C.
- •Treatment with known enzyme altering drugs.
- •History of allergic or adverse response to anastrozole or any comparable or similar product.
结局指标
主要结局
bioequivalence determined by statistical comparison Cmax
时间窗: 31 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Bioequivalency Study of Anastrozole 1 mg Under Fasted ConditionsBreast CancerNCT01155102Roxane Laboratories31
已完成
1 期
Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fed ConditionsBreast CancerNCT01367626Roxane Laboratories28
已完成
1 期
Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fasted ConditionsBreast CancerNCT01367652Roxane Laboratories28
已完成
1 期
Anastrozole 1 mg Tablets Under Fed ConditionsHealthyNCT01183390Teva Pharmaceuticals USA22
已完成
1 期
Anastrozole 1 mg Tablets Under Fasting ConditionsHealthyNCT01182181Teva Pharmaceuticals USA22